Muscle-Specific Receptor Tyrosine Kinase (MuSK) Myasthenia Gravis
- PMID: 27170368
- DOI: 10.1007/s11910-016-0668-z
Muscle-Specific Receptor Tyrosine Kinase (MuSK) Myasthenia Gravis
Abstract
Autoimmune myasthenia gravis (MG) is the prototypic, antibody-mediated neuromuscular disease and is characterized by a decrease in the number of functional acetylcholine receptors (AChR) within the muscle end plate zone of the neuromuscular junction (NMJ). Although the pathophysiology of AChR-mediated myasthenia gravis has been extensively studied over the last 40 years since its original description by Patrick and Lindstrom (Science 180:871-872, 1973), less is known about the much more recently described muscle-specific kinase (MuSK) antibody-mediated MG. MuSK-MG has features clinically distinct from Ach-R MG, as well as a different pattern of response to treatment and a unique immunopathogenesis.
Keywords: Acetylcholine receptor antibody; Muscle-specific receptor tyrosine kinase; Myasthenia gravis; Neuromuscular junction.
Similar articles
-
[Myasthenia gravis induced by autoantibodies against MuSK].Nihon Rinsho. 2008 Jun;66(6):1149-54. Nihon Rinsho. 2008. PMID: 18540361 Review. Japanese.
-
Neuromuscular junction autoimmune disease: muscle specific kinase antibodies and treatments for myasthenia gravis.Curr Opin Neurol. 2005 Oct;18(5):519-25. doi: 10.1097/01.wco.0000180660.57801.3f. Curr Opin Neurol. 2005. PMID: 16155434 Review.
-
[Clinical features of myasthenia related with autoantibodies to muscle specific tyrosine kinase (MuSK)].Zh Nevrol Psikhiatr Im S S Korsakova. 2010;110(12):72-6. Zh Nevrol Psikhiatr Im S S Korsakova. 2010. PMID: 21311492 Russian.
-
Antibody effector mechanisms in myasthenia gravis-pathogenesis at the neuromuscular junction.Autoimmunity. 2010 Aug;43(5-6):353-70. doi: 10.3109/08916930903555943. Autoimmunity. 2010. PMID: 20380584 Review.
-
Autoantibodies in myasthenia gravis.Int Rev Neurobiol. 2025;182:89-119. doi: 10.1016/bs.irn.2025.04.024. Epub 2025 Jul 4. Int Rev Neurobiol. 2025. PMID: 40675742 Review.
Cited by
-
Pembrolizumab-induced Ocular Myasthenia Gravis with Anti-titin Antibody and Necrotizing Myopathy.Intern Med. 2019 Jun 1;58(11):1635-1638. doi: 10.2169/internalmedicine.1956-18. Epub 2019 Feb 1. Intern Med. 2019. PMID: 30713313 Free PMC article.
-
Muscle-Specific Tyrosine Kinase and Myasthenia Gravis Owing to Other Antibodies.Neurol Clin. 2018 May;36(2):293-310. doi: 10.1016/j.ncl.2018.01.004. Neurol Clin. 2018. PMID: 29655451 Free PMC article. Review.
-
Telitacicept in combination with B-cell depletion therapy in MuSK antibody-positive myasthenia gravis: a case report and literature review.Front Immunol. 2024 Nov 18;15:1456822. doi: 10.3389/fimmu.2024.1456822. eCollection 2024. Front Immunol. 2024. PMID: 39624088 Free PMC article. Review.
-
Clinical Features of Myasthenia Gravis With Antibodies to MuSK Based on Age at Onset: A Multicenter Retrospective Study in China.Front Neurol. 2022 Apr 8;13:879261. doi: 10.3389/fneur.2022.879261. eCollection 2022. Front Neurol. 2022. PMID: 35463138 Free PMC article.
-
Efgartigimod for induction and maintenance therapy in muscle-specific kinase myasthenia gravis.Ther Adv Neurol Disord. 2025 Mar 21;18:17562864251326778. doi: 10.1177/17562864251326778. eCollection 2025. Ther Adv Neurol Disord. 2025. PMID: 40144041 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical